Internal Medicine
The Department of Internal Medicine is organized into 15 divisions that provide the excellent education, research, and patient care for which the department is renowned.
Our Mission
- To educate medical students, residents, and postdoctoral fellows in accordance with the highest professional standards
- To prepare clinicians to practice patient-centered, high-value, cost-conscious medicine of the highest standard
- To answer fundamental questions in the mechanisms, prevention and treatment of disease, in the basic sciences, and in health care delivery
As of 2026, the department had 1,122 faculty members: 839 with primary appointments, 118 more from other departments who held secondary appointments, and 165 with adjunct appointments. The primary and secondary faculty includes:
3
Nobel Prize winners
8
Members of the National Academy of Sciences
9
Members of the National Academy of Medicine
4
Members of the American Academy of Arts and Sciences
41
Members of the American Society for Clinical Investigation
28
Members of the Association of American Physicians
These exceptional faculty lead UT Southwestern Medical Center's Internal Medicine programs to produce graduates who balance the core responsibilities of medicine: selfless dedication, competence, and compassion. As with the rest of UT Southwestern, Internal Medicine is pursuing the future of medicine, today.
Spotlight on Internal Medicine Grand Rounds
Join us as Dr. Michael Welsh, a Professor of Internal Medicine at the University of Iowa, presents the Seldin Symposium Keynote Address during Internal Medicine Grand Rounds on Friday, April 3, at 8 a.m. in D1.502.
Dr. Welsh's groundbreaking work revealed that cystic fibrosis (CF) results from mutations to the CFTR protein, a chloride channel critical for airway hydration. His team demonstrated how these mutations repair chloride flow and pioneered strategies to "correct" defective CFTR, laying the foundation for therapies that now benefit about 90% of people with CF. This research ultimately enabled the development of a triple-drug combination that dramatically improves life expectancy, from the mid-30s for patients born before these therapies to potentially 80 years for babies born today.